# Luye Pharma Group

Source: https://onco.cc/companies/luye-pharma/  
OnCo record `luye-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Luye Pharma is a Chinese pharmaceutical group, listed in Hong Kong, whose oncology business rests on paclitaxel liposome (Lipusu) and other reformulated cancer medicines.

## Summary

Luye Pharma Group, based in Yantai in Shandong and listed on the Hong Kong stock exchange, develops and sells medicines in oncology, the central nervous system and cardiovascular disease, with a focus on new formulations and long-acting delivery. Its best-known cancer product is Lipusu, a liposomal formulation of paclitaxel widely used in China, and it runs phase 3 trials of reformulated chemotherapy and targeted agents. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Luye Pharma Group Ltd.; Luye Pharma; 绿叶制药; Shandong Boan Biotechnology Co., Ltd; Boan Biotech
- Tags: ctgov-sponsor
- HQ: Yantai
- Type: pharma
- Website: https://www.luye.cn

## Sources

- Official website: https://www.luye.cn
- ClinicalTrials.gov: trials led by Luye Pharma: https://clinicaltrials.gov/search?lead=Luye%20Pharma
- Wikipedia: https://en.wikipedia.org/wiki/Luye_Pharma_Group

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://onco.cc/trials/nct06022861/), [LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation](https://onco.cc/trials/nct07391566/), [Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC](https://onco.cc/trials/nct06496048/), [Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer](https://onco.cc/trials/nct06128837/)

---
JSON: https://onco.cc/api/v1/entities/luye-pharma.json